10.06.26 -- Vertex On Building Risk Into Manufacturing Network Strategy

Characterized by fewer studies, deeper characterization, and integrated process design, the lean biosimilar development model expands market access and brings treatment options to patients faster.

Computational fluid dynamics and metabolic modeling predict gas transfer more accurately than volumetric metrics, improving mammalian cell culture scale-up and process control.

Switch to rapid sequencing-based contaminant detection to accelerate advanced therapy release timelines, minimize batch rejection risks, and bypass slow, culture-based testing methods.

Secure domestic or diversified biopharma manufacturing to protect therapeutic development from supply chain disruptions, rising costs, and legislative tariff impacts.

N-1 perfusion technology increased antibody titers 1.5–4.5x over conventional fed-batch methods. See how high seed density and media blending cut costs and maximize suite utilization.

Development partnerships start with early alignment, transparency, and shared accountability, reducing risk, improving scalability, and supporting success as programs advance.

Delve into why investing in a comprehensive feasibility program for GOI testing is not just beneficial, but absolutely essential for cell and gene therapy companies.

By working with a single supplier that can handle the entire manufacturing value chain, companies can reduce risk, improve flexibility, and accelerate their time to market.

Iwan Bertholjotti, director of commercial bioconjugate development, and Dr. Bernhard Stump, head of bioconjugate development, discuss complexity and uncertainty in the bioconjugates market.